RE:RE:New Jason Napodano ArticleI agree with Jason in that Aralez will likely follow Depomed and Horizon growth trajectories over the coming 12-36 months. Didn't know that Vimovo royalties increase to 10% in 2016 so that was another intesting tidbit.